Investigation of the antiangiogenic behaviors of rivaroxaban and low molecular weight heparins

Basit Öğe Kaydı
dc.contributor.authorYavuz, Celal
dc.contributor.authorCaliskan, Ahmet
dc.contributor.authorKarahan, Oguz
dc.contributor.authorYazici, Suleyman
dc.contributor.authorGuclu, Orkut
dc.contributor.authorDemirtas, Sinan
dc.contributor.authorMavitas, Binali
dc.date.accessioned2024-04-24T17:08:19Z
dc.date.available2024-04-24T17:08:19Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractAntithrombotic agents play important roles in the prophylactic and therapeutic management of many cardiovascular disorders. Therefore, many researchers have focused on developing new strategies for anticoagulation. New oral anticoagulants and factor Xa inhibitors are products of such research. Although they are identified as advantageous, there are limited data available about their multisystemic interactions. Thus, the antiangiogenic behaviors of oral factor Xa inhibitors and low molecular weight heparins (LMWHs) were investigated in this study. The chick chorioallantoic membrane (CAM) model was designed to investigate the antiangiogenic potential of new oral factor Xa inhibitors (rivaroxaban) and LMWHs (enoxaparin sodium and tinzaparin sodium). Four different molar concentrations (10(-4), 10(-5), 10(-6), and 10(-7) mu mol/l) were studied for each drug. Each concentration was studied on 20 fertilized eggs. Vessel structures were evaluated under a stereoscopic microscope, and vessel formation was scaled according to previous literature. Both enoxaparin and tinzaparin sodium have increased antiangiogenic efficacy on CAM in a dose-dependent manner. However, this increased efficacy did not reach significant levels (average score < 0.5). On the contrary, while rivaroxaban showed dose-dependent antiangiogenic properties similar to enoxaparin and tinzaparin, a significant average antiangiogenic score (0.7) was detected at 10(-4) mu mol/l concentrations. New oral anticoagulants seem to be more favorable. However, their safety for the cardiovascular system needs to be clarified through microsystem studies on, for example, angiogenesis.en_US
dc.identifier.doi10.1097/MBC.0000000000000019
dc.identifier.endpage308en_US
dc.identifier.issn0957-5235
dc.identifier.issn1473-5733
dc.identifier.issue4en_US
dc.identifier.pmid24256628
dc.identifier.scopus2-s2.0-84900298174
dc.identifier.scopusqualityQ3
dc.identifier.startpage303en_US
dc.identifier.urihttps://doi.org/10.1097/MBC.0000000000000019
dc.identifier.urihttps://hdl.handle.net/11468/17296
dc.identifier.volume25en_US
dc.identifier.wosWOS:000335956900003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofBlood Coagulation & Fibrinolysis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLow Molecular Weight Heparinen_US
dc.subjectRivaroxabanen_US
dc.subjectAntiangiogenesisen_US
dc.subjectFactor Xa Inhibitorsen_US
dc.titleInvestigation of the antiangiogenic behaviors of rivaroxaban and low molecular weight heparinsen_US
dc.titleInvestigation of the antiangiogenic behaviors of rivaroxaban and low molecular weight heparins
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu